Item 2.02 Results of Operations and Financial Condition.

Finch Therapeutics Group, Inc. (the "Company") intends to share with investors the amount of cash and cash equivalents it had on hand as of December 31, 2021. Although the Company has not finalized its financial results for the twelve months ended December 31, 2021, the Company preliminarily estimates that its cash and cash equivalents as of December 31, 2021 was approximately $133.5 million.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2021 and its results of operations for the three months and year ended December 31, 2021. The audit of the Company's financial statements for the year ended December 31, 2021 is ongoing. The Company's actual consolidated cash and cash equivalents as of December 31, 2021 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures.

The information in this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

Mark Smith, PhD, the Company's Chief Executive Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 a.m. ET. The presentation will be webcast live and will be available under the "Events & Presentations" tab in the "Investors & News" section of the Company's website, located at www.finchtherapeutics.com.

On January 10, 2022, the Company posted an updated corporate presentation dated January 2022 providing a general corporate update to the business and disclosure regarding the Company's cash and cash equivalents as of December 31, 2021. The corporate presentation is available under the "Events & Presentations" tab in the "Investors & News" section of the Company's website, located at www.finchtherapeutics.com. The Company intends to use this presentation in meetings with analysts, investors and others from time to time.

The information contained in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit   Description
  No.

99.1        Corporate Presentation, dated January 2022  .

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses